References
- Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. 2001. Antineoplastic agents. In: Gilman AG, editor. The pharmacological basis of therapeutics. 10th ed. New York: Macmillan Publishing Co. pp 1389–1461.
- DiFrancesco R, Griggs JJ, Donnelly J, Dicenzo R. 2007. Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B 852:545–553.
- Fahmy OT, Korany MA, Maher HM. 2004. High performance liquid chromatographic determination of some co-administered anticancer drugs in pharmaceutical preparations and in spiked human plasma. J Pharm Bio Anal 34:1099–1107.
- Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. 1983. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361–369.
- Houze P, Deschamps F, Dombret H, Bousquet B, Gourmel B. 2001. Micellar electronic capillary chromatograph quantification of cytosine arabinoside and its metabolite, uracil arabinoside, in human serum. J Chromatogr B 754:185–192.
- Hsieh Y, Duncan CJG, Liu Ming. 2007. A mixed-mode liquid chromatography–tandem mass spectrometric method for the determination of cytarabine in mouse plasma. J Chromatogr B 854:8–12.
- Kromidas S. 2000. Practical problem solving in HPLC. Weinheim, Germany: Wiley-VCH Verlag GmbH.
- Larson RR, Khazaeli MB, Dillon HK. 2003. Development of an HPLC method for simultaneous analysis of five antineoplastic agents. Appl Occup Environ Hyg 18:109–119.
- Lloyd DK, Cypess AM, Wainer IW. 1991. Determination of cytosine-beta-D-arabinoside in plasma using capillary electrophoresis. J Chromatogr 568:117–124.
- Mahoney BP, Raghunand Baggett, NB, Gillies RJ. 2003. Tumor acidity, ion trapping and chemotherapeutics. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207–1218.
- Manallack DT. 2007. The pKa distribution of drugs: application to drug discovery. Perspect Medicin Chem 1:25–38.
- Novotny L, Vachalkova A. 1993. Polarographic study of cytosine nucleosides. Neoplasma 40:369–372.
- Physician’s Desk References Electronic Library. 2003. Ver.6.0.0a. 57th ed. Medical Electronics.
- Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. 1985. Pharmacology directed ara-C therapy for refractory leukaemia. Semin Oncol 12(Suppl 3):20–30.
- Rustum YM. 1978. Metabolism and intracellular retention of 1-β-D-arabinofuranosylcytosine as predictors of response of animal tumors. Cancer Res 38:543–9.
- Snyder LR, Kirkland JJ, Glajch JL. 1988. Practical HPLC method development. New York: Wiley, John & Sons, Inc.
- Snyder LR, Kirkland JJ, Glajch JL. 1997. Practical HPLC method development. 2nd ed. New York: Wiley, John & Sons, Inc.
- Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. 1967. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20:333–353.
- Trittler R. 2006. Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS. Eur J Hosp Pharm Sci 1:10–12.
- USA Department of Health,and Human Services, FDA, Center for Drug Evaluation and Research (CDER.%Ee, Center for Veterinary Medicine. 2001. Guidance for industry, bioanalytical method validation. Rockville, USA: FDA, CDER.
- van Asperen J, van Telligen O, Beijnen JH. 1998. Determination of doxorubicin and its metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B 712:129–143.
- Wei G, Xiao S, Si D, Liu C. 2008. Improved HPLC method for quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations. Bio Chrom 22:1252–1258.